This in vitro assay provides supporting evidence to the ACMG/AMP guidelines used to guide clinical interpretation of BAP1 variants in the context of dominant cancer predisposition and the neurodevelopmental Kury-Isidor syndrome. This evidence concerns the gene BAP1 and Kury-Isidor syndrome.